Ordering Recommendation

Qualitative test to monitor medication compliance and to detect undisclosed drug/substance use in support of pain management, substance use disorders treatment, and other pharmacotherapies involving controlled substances.

If expert result interpretation is desired, refer to Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2009288). For a traditional screen with reflex to secondary quantitative testing, refer to Drug Profile, Screen with Reflex to Quantitation (2012312).

This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation

Random urine.

Specimen Preparation

Transfer 4 mL each into two (2) ARUP standard transport tubes of urine with no additives or preservatives. (Min: 2 mL each)

Storage/Transport Temperature


Unacceptable Conditions

Specimens exposed to repeated freeze/thaw cycles.


Ambient: 1 week (Clonazepam may be unstable at ambient condition beyond three days); Refrigerated: 1 month; Frozen: 1 month


Qualitative Tandem Mass Spectrometry/Qualitative Enzyme Multiplied Immunoassay Technique (EMIT)/Qualitative Spectrophotometry




1-3 days

Reference Interval

Drugs covered and range of cutoff concentrations.
Note: Some drugs are identified based on the presence of unique drug metabolites not listed below.
Drugs/Drug Classes
Range of Cutoff Concentrations
Barbiturates 200 ng/mL
alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, zolpidem
20 - 60 ng/mL
Cannabinoids (11-nor-9-carboxy-THC) 50 ng/mL
Ethyl Glucuronide 500 ng/mL
Muscle Relaxant(s):
carisoprodol, meprobamate
100 ng/mL
buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone, oxycodone, oxymorphone, tapentadol, tramadol
2-200 ng/mL
GABA analogues:
Gabapentin, pregabalin
3,000 ng/mL
Phencyclidine (PCP) 25 ng/mL
amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine
50-200 ng/mL

Interpretive Data

Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry

The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.

For medical purposes only; not valid for forensic use.

Compliance Category

Laboratory Developed Test (LDT)


Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.

Hotline History


CPT Codes

80326; 80347; 80364; 80355; 80307 (Alt code: G0481)


Component Test Code* Component Chart Name LOINC
0090386 Creatinine, Urine 2161-8
2007636 Codeine, U 3507-1
2007637 Morphine, U 3830-7
2007638 6-acetylmorphine, U 10976-9
2007640 Oxycodone, U 10998-3
2007641 Noroxycodone, U 61424-8
2007642 Oxymorphone, U 11247-4
2007643 Noroxymorphone, U 89302-4
2007644 Hydrocodone, U 12308-3
2007646 Norhydrocodone, U 61421-4
2007647 Hydromorphone, U 9834-3
2007649 Buprenorphine, U 3414-0
2007651 Norbuprenorphine, U 58362-5
2007652 Fentanyl, U 11235-9
2007653 Norfentanyl, U 43199-9
2007654 Meperidine metabolite, U 58388-0
2007655 Tapentadol, U 72485-6
2007656 Tapentadol-o-Sulf, U 72485-6
2007658 Methadone Screen, U 3773-9
2007660 Tramadol Screen, U 43219-5
2007662 Amphetamine, U 19343-3
2007663 Methamphetamine, U 3779-6
2007664 MDMA, U 14267-9
2007665 MDA, U 42253-5
2007666 MDEA, U 61048-5
2007668 Phentermine, U 3957-8
2007670 Cocaine Screen, U 3393-6
2007672 Alprazolam, U 9351-8
2007673 Alpha-OH-Alprazolam, U 61036-0
2007674 Clonazepam, U 19245-0
2007675 7-Aminoclonazepam, U 61030-3
2007676 Diazepam, U 3550-1
2007677 Nordiazepam, U 3861-2
2007678 Oxazepam, U 12361-2
2007679 Temazepam, U 61060-0
2007680 Lorazepam, U 18187-5
2007681 Midazolam, U 19585-9
2007682 Zolpidem, U 33338-5
2007684 Barbiturates Screen, U 3377-9
2007687 Ethyl Glucuronide Screen, U 55349-5
2007688 THC (Cannabinoids) Screen, U 3435-5
2007689 Phencyclidine Screen, U 3936-2
2007690 Carisoprodol Screen, U 21142-5
2007691 Targeted Drug Profile Comment 8251-1
2008312 EER Targeted Drug Profile, U 11526-1
2013281 Methylphenidate, U 3808-3
3003499 Alpha-OH-Midazolam, U 94108-8
3003500 Zolpidem Metabolite, U 94103-9
3003501 Gabapentin, U 92648-5
3003502 Naloxone, U 92649-3
3003503 Pregabalin, U 92651-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • abstinence verification
  • addiction management
  • Comprehensive hybrid
  • drug screen
  • high res
  • high-res
  • hybrid
  • medication adherence
  • medication compliance
  • Pain management
  • prenatal drug screen
  • substance use disorder
  • targeted
  • urine
Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine